Results

Xilio Therapeutics Inc.

01/20/2022 | Press release | Archived content

Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors